Baseline patient, disease, and HCT variables 13
| Variables . | Moffitt (n = 24) . | FHCRC (n = 9) . | UMN (n = 5) . | Total (n = 38) . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, median year (range) | 54.5 (26-73) | 69 (38-84) | 63 (31-69) | 59.5 (26-84) | .022 | |||||
| Gender | Female | 7 | 29.2% | 4 | 44.4% | 2 | 40% | 13 | 34.2% | .68 |
| Male | 17 | 70.8% | 5 | 55.6% | 3 | 60% | 25 | 65.8% | ||
| Disease | AML | 10 | 41.7% | 2 | 22.2% | 2 | 40% | 14 | 36.8% | .55 |
| MDS | 4 | 16.7% | 4 | 44.4% | 1 | 20% | 9 | 23.7% | ||
| MN | 3 | 12.5% | 0 | 0% | 1 | 20% | 4 | 10.5% | ||
| ALL | 3 | 12.5% | 0 | 0% | 1 | 20% | 4 | 10.5% | ||
| NHL | 3 | 12.5% | 2 | 22.2% | 0 | 0% | 5 | 13.2% | ||
| HL | 1 | 4.2% | 0 | 0% | 0 | 0% | 1 | 2.6% | ||
| MM | 0 | 0% | 1 | 11.1% | 0 | 0% | 1 | 2.6% | ||
| HCT-CI, median (range) | 3.5 (0-8) | 4 (2-5) | 6 (1-9) | 4 (0-9) | .59 | |||||
| KPS | 80%-100% | 22 | 91.7% | 6 | 66.7% | 3 | 60% | 31 | 81.6% | .21 |
| <80% | 2 | 8.3% | 2 | 22.2% | 1 | 20% | 5 | 13.2% | ||
| Missing | 0 | 0% | 1 | 11.1% | 1 | 20% | 2 | 5.3% | ||
| Graft source | BM | 0 | 0% | 0 | 0% | 1 | 20% | 1 | 2.6% | .0003 |
| PBSC | 24 | 100% | 9 | 100% | 2 | 40% | 35 | 92.1% | ||
| UCB | 0 | 0% | 0 | 0% | 2 | 40% | 2 | 5.3% | ||
| Graft type | MMUD | 2 | 8.3% | 1 | 11.1% | 0 | 0% | 3 | 7.9% | .013 |
| MRD | 5 | 20.8% | 2 | 22.2% | 2 | 40% | 9 | 23.7% | ||
| MUD | 17 | 70.8% | 6 | 66.7% | 1 | 20% | 24 | 63.2% | ||
| UCB | 0 | 0% | 0 | 0% | 2 | 40% | 2 | 5.3% | ||
| Variables . | Moffitt (n = 24) . | FHCRC (n = 9) . | UMN (n = 5) . | Total (n = 38) . | P value . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age, median year (range) | 54.5 (26-73) | 69 (38-84) | 63 (31-69) | 59.5 (26-84) | .022 | |||||
| Gender | Female | 7 | 29.2% | 4 | 44.4% | 2 | 40% | 13 | 34.2% | .68 |
| Male | 17 | 70.8% | 5 | 55.6% | 3 | 60% | 25 | 65.8% | ||
| Disease | AML | 10 | 41.7% | 2 | 22.2% | 2 | 40% | 14 | 36.8% | .55 |
| MDS | 4 | 16.7% | 4 | 44.4% | 1 | 20% | 9 | 23.7% | ||
| MN | 3 | 12.5% | 0 | 0% | 1 | 20% | 4 | 10.5% | ||
| ALL | 3 | 12.5% | 0 | 0% | 1 | 20% | 4 | 10.5% | ||
| NHL | 3 | 12.5% | 2 | 22.2% | 0 | 0% | 5 | 13.2% | ||
| HL | 1 | 4.2% | 0 | 0% | 0 | 0% | 1 | 2.6% | ||
| MM | 0 | 0% | 1 | 11.1% | 0 | 0% | 1 | 2.6% | ||
| HCT-CI, median (range) | 3.5 (0-8) | 4 (2-5) | 6 (1-9) | 4 (0-9) | .59 | |||||
| KPS | 80%-100% | 22 | 91.7% | 6 | 66.7% | 3 | 60% | 31 | 81.6% | .21 |
| <80% | 2 | 8.3% | 2 | 22.2% | 1 | 20% | 5 | 13.2% | ||
| Missing | 0 | 0% | 1 | 11.1% | 1 | 20% | 2 | 5.3% | ||
| Graft source | BM | 0 | 0% | 0 | 0% | 1 | 20% | 1 | 2.6% | .0003 |
| PBSC | 24 | 100% | 9 | 100% | 2 | 40% | 35 | 92.1% | ||
| UCB | 0 | 0% | 0 | 0% | 2 | 40% | 2 | 5.3% | ||
| Graft type | MMUD | 2 | 8.3% | 1 | 11.1% | 0 | 0% | 3 | 7.9% | .013 |
| MRD | 5 | 20.8% | 2 | 22.2% | 2 | 40% | 9 | 23.7% | ||
| MUD | 17 | 70.8% | 6 | 66.7% | 1 | 20% | 24 | 63.2% | ||
| UCB | 0 | 0% | 0 | 0% | 2 | 40% | 2 | 5.3% | ||
ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BM, bone marrow; FHCRC, Fred Hutchinson Cancer Research Center; HCT-CI, HCT comorbidity index; HL, Hodgkin lymphoma; KPS, Karnofsky performance status; MN, myeloproliferative neoplasms (including chronic myeloid leukemia, and primary myelofibrosis); MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma (including follicular lymphoma, mantle cell lymphoma, and small lymphocytic lymphoma); PBSC, peripheral blood mobilized stem cells; UCB, umbilical cord blood; UMN, University of Minnesota.